Back to discover
Disease

Spinal Fractures

Clinical development underwayEmerging research
MeSHSpinal Fractures
2
Publications
2
Clinical trials
2021
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 safety action from EMA issued.
Major developments
Major safety communicationImportant
Market withdrawal — Zoledronic acid
Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).2026-03-13
Regulatory Updates1View
  • 2026-03-13Market withdrawal — Zoledronic acidPrevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Activity timeline1
  • 2026-03-13RegulatoryMarket withdrawal — Zoledronic acidPrevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH).

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Zoledronic acidapproved

Approval — Prevention of skeletal related events (pathological fractures, spinal compression, radiat… (2014)

Clinical trials

2 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
2
All trials
0
Active
0
Late-stage
1
Completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2014emaApproval — Zoledronic acid· Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH). source ↗
2012emaApproval — Zoledronic acid· Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone; treatment of adult patients with tumour-induced hypercalcaemia (TIH). source ↗
2001emaApproval — Zoledronic acid· Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; treatment of tumour-induced hypercalcaemia (TIH); prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; treatment of tumour-induced hypercalcaemia (TIH); prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone; treatment of adult patients with tumour-induced hypercalcaemia (TIH). source ↗
Safety updates
2026emaMarket withdrawal — Zoledronic acid· Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH). source ↗
2024emaMarket withdrawal — Zoledronic acid· Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia. source ↗
2024emaMarket withdrawal — Zoledronic acid· 4 mg / 5 ml and 4 mg / 100 ml: Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH). 5 mg / 100 ml: Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: in post-menopausal women; in men; at increased risk of fracture. Treatment of Paget's disease of the bone in adults. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20042021
Leading journals2
  • JAMA network open1
  • The New England journal of medicine1
Leading researchers8
  • Bone HG1
  • Cai S1
  • Chen L1
  • Cui L1
  • Cummings SR1
  • Deng Y1
  • Devogelaer JP1
  • Ding X1
Affiliations (unnormalised)6
  • Beijing Center for Diseases Prevention and Control1
  • Center of Osteoporosis1
  • Chengdu Military General Hospital1
  • Chongqing Center for Disease Control and Prevention1
  • Guangdong Provincial Center for Disease Control and Prevention1
  • Guangdong Provincial People's Hospital1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Broken bones in the vertebral column.

Identifiers
MeSHSpinal Fractures
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.